🇺🇸 FDA
Patent

US 10221226

LEDGF peptides and formulations thereof for treatment of degenerative disorders

granted A61KA61K38/00A61K38/18

Quick answer

US patent 10221226 (LEDGF peptides and formulations thereof for treatment of degenerative disorders) held by The Regents of the University of Colorado, a Body Corporate expires Mon Feb 28 2039 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Regents of the University of Colorado, a Body Corporate
Grant date
Tue Mar 05 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Feb 28 2039 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
17
CPC classes
A61K, A61K38/00, A61K38/18, A61K47/52, A61K47/6929